Cas 49765-05-1,(Z)-ethyl 3-aMino-4,4,4-trichloro-2-cyanobut-2-enoate

49765-05-1

Post Buying Request

Basic information

Product Name: (Z)-ethyl 3-aMino-4,4,4-trichloro-2-cyanobut-2-enoate
Synonyms: (Z)-ethyl 3-aMino-4,4,4-trichloro-2-cyanobut-2-enoate;(Z)-ethyl 2-(2-((tert-butoxycarbonyl)aMino)cyclohexylidene)acetate;ethyl(Z)-3-amino-4,4,4-trichloro-2-cyanobut-2-enoate;ETHYL (2Z)-3-AMINO-4,4,4-TRICHLORO-2-CYANOBUT-2-ENOATE;EOS-61557
CAS NO:49765-05-1
Molecular Formula: C₇H₇Cl₃N₂O₂
Molecular Weight: 283.3633
EINECS: N/A
Product Categories: N/A
Mol File: 49765-05-1.mol

Chemical Properties

Melting Point: N/A
Boiling Point: N/A
Flash Point: N/A
Appearance: /
Density: N/A
Refractive Index: N/A
Storage Temp.: N/A
Solubility: N/A
CAS DataBase Reference: (Z)-ethyl 3-aMino-4,4,4-trichloro-2-cyanobut-2-enoate(CAS DataBase Reference)
NIST Chemistry Reference: (Z)-ethyl 3-aMino-4,4,4-trichloro-2-cyanobut-2-enoate(49765-05-1)
EPA Substance Registry System: (Z)-ethyl 3-aMino-4,4,4-trichloro-2-cyanobut-2-enoate(49765-05-1)

Safety Data

Hazard Codes: N/A
Statements: N/A
Safety Statements: N/A
WGK Germany:
RTECS:
HazardClass: N/A
PackingGroup: N/A
Hazardous Substances Data: 49765-05-1(Hazardous Substances Data)

Suppliers
Usage
Upstream product
Downstream Products
Article

49765-05-1 Suppliers

Recommended suppliers

49765-05-1 Usage

Uses

2-Bromo-4,6-difluorobenzaldehyde (cas# 154650-59-6) is a useful research chemical.

Check Digit Verification of cas no

The CAS Registry Mumber 49765-05-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,9,7,6 and 5 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 49765-05:
(7*4)+(6*9)+(5*7)+(4*6)+(3*5)+(2*0)+(1*5)=161
161 % 10 = 1
So 49765-05-1 is a valid CAS Registry Number.

49765-05-1Upstream product

49765-05-1Downstream Products

6825-71-4 3,5-diamino-1H-pyrazole-4-carboxylic acid ethyl ester

49765-05-1Relevant academic research and scientific papers

Alkyne derivative, preparation method and application thereof

-

Paragraph 0065-0071, (2021/01/20)

The invention relates to an alkyne derivative and a preparation method thereof and application of the alkyne derivative in medicine, specifically to an alkyne derivative represented by general formula(I), a preparation method and a pharmaceutically accept

MACROCYCLE CONTAINING AMINOPYRAZOLE AND PYRIMIDINE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

-

Paragraph 0118-0119, (2020/07/15)

The present application relates to a macrocycle containing aminopyrazole and pyrimidine, which is represented by formula (I), a pharmaceutical composition thereof, and a use thereof in inhibiting tropomyosin receptor kinase (Trk) activity and in treating diseases in mammals that are mediated by Trk.

AMINO PYRAZOLOPYRIMIDINE COMPOUND USED AS NEUROTROPHIC FACTOR TYROSINE KINASE RECEPTOR INHIBITOR

-

Paragraph 0113-0115, (2019/09/15)

Provided is an amino pyrazolopyrimidine compound as represented by the following structural formula used as a neurotrophic factor tyrosine kinase receptor inhibitor. The compound can inhibit the activity of Trk kinase and can treat diseases mediated by a Trk tyrosine kinase receptor in mammals.

Neurotrophic factor tyrosine kinase receptor inhibitor

-

Paragraph 0849; 0851-0853, (2018/05/30)

The invention provides a neurotrophic factor tyrosine kinase receptor inhibitor. The tyrosine kinase receptor inhibitor provided by the invention has a tricyclic parent core structure, can inhibit theactivity of Trk kinase and can be used for treating mammalian diseases mediated by the Trk kinase.

Substituted heteroaryl compounds and compositions and uses thereof

-

Paragraph 0463-0466, (2017/12/02)

The invention discloses a substituted ceteroary compound as well as a composition and an application thereof. The compound is a compound shown in a formula (I) or a stereisomer, a tautomer, a nitric oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or prodrug of the compound shown in the formula (I). The invention further discloses a pharmaceutical composition including the compound. The compound and the pharmaceutical composition are capable of adjusting the activity of the AK kinase and can be used for preventing, processing, treating and relieving the JAK-mediated disease or disorder.

SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE

-

Paragraph 316; 366, (2015/06/03)

The present invention provides novel heterocyclic compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a JAK-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of JAK-mediated disease.

PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS

-

Page/Page column 110, (2011/02/24)

A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 49765-05-1